CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 43,626 enrolled
Drug / intervention
Ringer's lactate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04512950
NCT04512950Phase 4Completed
CompareCT.gov

Crystalloid FLUID Choices for Resuscitation of Hospital Patients: A Pragmatic Cluster Cross Over Trial

Ottawa Hospital Research Institute·interventional·Posted Aug 14, 2020·Updated May 2, 2025

In Brief

A Phase 4 clinical trial evaluating Ringer's lactate and 0.9% saline for Fluid Therapy. Completed, enrolled 43,626 participants across 7 sites.

Detailed Summary

The aim of the FLUID Trial is to conduct a pragmatic, multi-centre, open label randomized cluster cross-over trial (RCT) to determine whether fluid administration with 0.9% saline as compared to Ringer's lactate decreases death or re-admission to hospital with 90 days of the index admission.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFluid Therapy
CountriesCanada
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 14, 2020
Enrollment StartAug 15, 2016
Primary CompletionJun 13, 2020
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 5.9 years ago

Interventions

Ringer's lactatedrug

Half of the hospitals will be randomized to Ringer's Lactate for a 12 week study period; after a 2 week run-out, the study fluid will be switched to 0.9% saline for another 12 week study period, followed by a 2 week run-out.

0.9% salinedrug

Half of the hospitals will be randomized to 0.9% saline for a 12 week study period; after a 2 week run-out, the study fluid will be switched to Ringer's Lactate for another 12 week study period, followed by a 2 week run-out.